Get the Stockscreener App
0.021
0.00%
0.00
Virpax Pharmaceuticals Inc stock is traded at $0.021, with a volume of 2,535.
It is up +0.00% in the last 24 hours and up +0.00% over the past month.
See More
Previous Close:
$0.021
Open:
$0.021
24h Volume:
2,535
Relative Volume:
6.52
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-13.24M
P/E Ratio:
-0.00238
EPS:
-8.83
Net Cash Flow:
$-16.85M
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
-91.32%
1Y Performance:
-99.74%
1-Day Range:
$0.021
$0.021
1-Week Range:
$0.021
$0.021
52-Week Range:
$0.01
$0.2869
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Name
Virpax Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare VRPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.021 | 0 | 0 | -13.24M | -16.85M | -8.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.96 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
851.42 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.17 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.67 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Virpax Pharmaceuticals Inc Stock (VRPX) Latest News
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference - MSN
Virpax Pharmaceuticals Inc. (VRPX) Stock Price | Live Quotes & Charts | EXPM - StocksToTrade
Analyzing Virpax Pharmaceuticals (NASDAQ:VRPX) and IMV (OTCMKTS:IMVIQ) - Defense World
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Virpax Pharmaceuticals, Inc.Common Stock (NQ: - FinancialContent
Nanotechnology Stocks To Watch Today – September 1st - Defense World
Head-To-Head Comparison: Virpax Pharmaceuticals (NASDAQ:VRPX) vs. Evotec (OTCMKTS:EVTCY) - Defense World
Virpax reports positive study results for pain management drug - MSN
Top Nanotechnology Stocks To Follow Today – August 25th - Defense World
Promising Nanotechnology Stocks To Watch Now – July 16th - Defense World
Promising Nanotechnology Stocks To Watch NowJuly 16th - MarketBeat
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading Down 2.9% – Should You Sell? - Defense World
Promising Nanotechnology Stocks To Add to Your Watchlist – July 9th - Defense World
Top Nanotechnology Stocks To Follow NowJuly 10th - MarketBeat
Promising Nanotechnology Stocks To Add to Your WatchlistJuly 9th - MarketBeat
Nanotechnology Stocks To Watch Today – July 7th - Defense World
Nanotechnology Stocks To Research – July 3rd - Defense World
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment - StatNano
VRPX Stock Price and Chart — OTC:VRPX - TradingView
VRPX stock plunges to 52-week low, touches $1.07 - Investing.com Australia
Virpax Pharmaceuticals Faces Nasdaq Delisting Notice and Leadership Changes - TipRanks
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com
Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com
Virpax receives positive Probudur™ results for dose range study - TradingView
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET - MyChesCo
Could This Needle-Free COVID Vaccine Technology Transform Vaccine Delivery? - Stock Titan
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - Stock Titan
Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Virpax lauds Nanomerics’ MET study with no severe side effects By Investing.com - Investing.com South Africa
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate - Yahoo Finance
Virpax Pharmaceuticals Announces Positive Results from U.S. Army Study on Probudur™ - Kalkine Media
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering - FinancialContent
Virpax Pharmaceuticals sets public offering at $0.20 per share - Investing.com
Virpax Pharmaceuticals enacts reverse stock split - Investing.com
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Virpax Pharmaceuticals appoints new CFO By Investing.com - Investing.com Canada
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
VRPX stock touches 52-week low at $0.46 amid market challenges - Investing.com
Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy, Price Target is $173 - marketscreener.com
Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com
Virpax Pharmaceuticals extends financing negotiation rights By Investing.com - Investing.com UK
Virpax Pharmaceuticals announces auditor change and board resignation By Investing.com - Investing.com Canada
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments - Business Wire
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - MarketScreener
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15 - FinancialContent
Virpax Pharmaceuticals pays off $2.5 million secured note early - Investing.com
Virpax Regains Compliance with Nasdaq Minimum Bid Price | User | ricentral.com - FinancialContent
3 Penny Stocks to Watch Now, 7/23/24 - Nasdaq
Virpax Pharmaceuticals Inc Stock (VRPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
1.90%
Cap:
|
Volume (24h):